Incannex Healthcare (IXHL) Cash from Operations (2023 - 2026)
Incannex Healthcare (IXHL) posted quarterly Cash from Operations of 2441000.0 for Q1 2026, up 22.04% year-on-year from 2000201.78 in Q1 2025, and up 46.93% on a QoQ basis from 4600000.0 in Q4 2025.
Incannex Healthcare (IXHL) Cash from Operations (2023 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Cash from Operations for 4 consecutive years, with 2441000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations rose 22.04% year-over-year to 2441000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17723000.0 (down 20.79% YoY) and the FY2025 annual result came in at 12513000.0, up 21.03% from the prior year.
- Cash from Operations grew to 2441000.0 in Q1 2026 per IXHL's latest filing, from 4600000.0 in the prior quarter.
- Over the last five years, Cash from Operations for IXHL reached as high as 1482000.0 in Q2 2025 and fell as low as 9200000.0 in Q3 2025.
- A 4-year average of 3839307.69 and a median of 3131000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 60.95% — and 2025, when it slumped 309.8%.
- Year by year, Cash from Operations stood at 2103000.0 in 2023, then sank by 168.9% to 5655000.0 in 2024, then climbed by 18.66% to 4600000.0 in 2025, then soared by 46.93% to 2441000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2441000.0, 4600000.0, and 9200000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 463.30 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Incannex Healthcare | 37.29 Mn | 37.29 Mn | - | -2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.44 Mn |
| Mar 31, 2026 | -2.44 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | -3.13 Mn |
| Mar 31, 2025 | -3.13 Mn |
| Dec 31, 2024 | -5.66 Mn |
| Dec 31, 2024 | -5.66 Mn |
| Sep 30, 2024 | -2.25 Mn |
| Sep 30, 2024 | -2.25 Mn |
| Jun 30, 2024 | -3.64 Mn |
| Jun 30, 2024 | -3.64 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Dec 31, 2023 | -2.10 Mn |
| Dec 31, 2023 | -2.10 Mn |